Last Updated on January 20, 2024 by The Health Master
The Maharashtra Food and Drugs Administration (FDA) has set timelines for various regulatory approvals with the aim of making the approval process transparent and facilitating the ease of doing business.
On August 22, 2022, the FDA came up with a circular prescribing timeline for various applications. As per the circular, the prescribed timeline for drug manufacturers’ plant layout approval is 14 days.
Similarly, the prescribed time period for a grant for new licenses and loan licenses is 35 days and 14 days, respectively. The prescribed time period for brand change approval is 4 days.
The notice stated that the state FDA will grant approval for the additional product from the same site for export in 10 days, while approval for the additional product from the same manufacturing plant for the domestic market will be issued in 20 days, stated the notice.
The prescribed timeline for grant of various certificates viz, WHO-GMP certificates, certificate of pharmaceutical product (CPP or CoPP) is 7 days.
The time prescribed for district and division offices is seven working days. The time prescribed for head office is five working days.
As per the rule, applicants are required to submit an application for a grant of WHO-GMP certificates to the Central Drugs Standard Control Organisation (CDSCO) and the state FDA.
The application scrutiny is conducted by CDSCO followed by a joint inspection of the manufacturing plant by CDSCO and an FDA inspector.
Deficiencies, if any, observed during the joint inspection are communicated to manufacturers.
Once manufacturers submit a compliance report, it is verified by the state FDA and a grant of the WHO-GMP certificate along with products is recommended.
The state FDA has provided an online software system for the grant of WHO-GMP certificates, CoPP, etc.
Timelines are prescribed for the disposal of application after the recommendations of the joint inspection team and CDSCO vide circular dated May 31, 2022.
Dr Gahane, joint commissioner, headquarters, controlling authority, FDA, Maharashtra, “Earlier there were no timelines for approval of various applications.
For the first time, we came out with specific timelines for various regulatory approvals. It will make the approval process transparent and facilitate ease of doing business.”
He was speaking at “Reinvigorating India’s Pharma Exports: Awareness Workshop on Export Incentives” held by the Pharmaceutical Export Promotion Council of India on August 26, 2022.
Dr Gahane said besides this, we are also planning to issue CoPP certificates with digital signatures which can be downloaded by manufacturers at their premises.
It will further facilitate ease of doing business in the state, he added.
He also shed light on the collaborative support of the FDA to manufacturers and exporters for regulatory compliance with international standards.
USFDA issues Form 483 with one observation to Aurobindo Pharma subsidiary’s plant
USFDA gives tentative nod for Dasatinib tablets
Pharma company fined for dumping medical waste in open
USFDA issues Form 483 with 6 observations to Cipla
Penalty provision for Blood Banks / Centres not updating stock in time
Govt invites eligible Medical Devices Firms Category B of PLI scheme
Drug Rules 1945 amended to allow parallel submission of manufacturing & marketing approvals
This Air is an essential element for the Tablet Coating Process
NPPA fixes Retail Prices of 45 drug formulations
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
